For release Tuesday, June 16, 2020, 12 pm EDT For information contact John M. Clymer, Executive Director, 202-903-7303 or john.clymer@nationalforum.org NATIONAL FORUM AND PARTNERS URGE CONGRESS AND ADMINISTRATION TO INCREASE PATIENTS’ ACCESS TO HEALTHCARE, TEAM-BASED CARE Today, the National Forum for Heart Disease & Stroke Prevention and …
National Forum Statement about ICER’s Announced Assessment of New Cholesterol Medications
The National Forum released the following statement about the Institute for Clinical and Economic Review’s (ICER’s) announcement today that it will conduct value assessments of inclisiran and bempadoic acid, two new treatments for high cholesterol. The Value & Access Steering Committee (VASC), convened by the National Forum and representing …
Value & Access Steering Committee & Partners Comment on ICER Draft Evidence Report on Additive CVD Therapies
The National Forum submitted to the Institute for Clinical and Economic Review (ICER) feedback from the Value & Access Steering Committee and partners on ICER’s Draft Evidence Report on Additive Cardiovascular Disease Therapies. The feedback reflects the consensus of Value & Access Steering Committee members and partners who represent …
National Forum for Heart Disease & Stroke Prevention Announces New Chair of Value & Access Initiative
FOR IMMEDIATE RELEASE National Forum for Heart Disease & Stroke Prevention Announces New Chair of Value & Access Initiative WASHINGTON, DC, July 25, 2019 – The National Forum for Heart Disease & Stroke Prevention announced that Michael Cropp, MD, MBA, President & CEO of Independent Health will serve as the Chair of the …
Immediate Past National Forum Board Chair, Dr. Jennifer Robinson, lead author on Updated Guidance from the NLA Identifying Patients in Which PCSK9i Use Provides Reasonable Value
During it's 2019 Scientific Sessions, the National Lipid Association (NLA) released a statement paper, led by Dr. Jennifer Robinson, Immediate Past National Forum Board Chair. The paper provides updated guidance to clinicians with identifying patient groups in which use of PCSK9 monoclonal antibodies (mAbs) provides a reasonable value. Read the …
National Forum Statement on Praluent Price Change
The National Forum issued the following statement in response to Sanofi and Regeneron’s announcement that they cut the list price of their LDL (“bad”) cholesterol-lowering treatment, Praluent, to $5,850 annually, a 60 percent reduction from the original list price. Amgen announced a similar price reduction in October 2018 on Repatha. Both Praluent …
National Forum Statement on Amgen’s Repatha Price Change
The National Forum issued the following statement in response to Amgen's announcement that it cut the price of its cholesterol-lowering drug, Repatha, by 60 percent. Leaders representing patients, providers, public health, payers and pharma/biotech have joined forces through the National Forum Value & Access Initiative to enhance health and …
New York Times Article: These Cholesterol-Reducers May Save Lives. So Why Aren’t Heart Patients Getting Them?
10/2/18 - New York Times article …
Value & Access Steering Committee & Partners Comment on ICER Draft Scope for Review of Canakinumab’s ASCVD Indication
A summary of feedback from the National Forum's Value & Access Initiative Steering Committee and partners engaged in the value & access space on the Institute for Clinical and Economic Review (ICER)'s draft scope for review of canakinumab's ASCVD indication View the document …